Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab
2020; Cureus, Inc.; Linguagem: Inglês
10.7759/cureus.8072
ISSN2168-8184
AutoresCagney Cristancho, Ivy Riano, Daniel Guareras-Paredes, Robin Park, Kala Seetharaman,
Tópico(s)Cutaneous Melanoma Detection and Management
ResumoLocally advanced cutaneous squamous cell carcinoma (cSCC) represents a challenge in treatment. Only very recently (February 2020) have guidelines been released regarding the management of unresectable, locally advanced cSCC. With the introduction of check point inhibitors during the last decade, anti-PD-1 antibodies represent a novel immunotherapeutic strategy in cancer. We present a case of an advanced cSCC not amenable to surgical resection, who experienced dramatic improvement following treatment with the programmed cell death protein 1 receptor (PD-1) inhibitor pembrolizumab as an immunotherapeutic strategy.
Referência(s)